Aktuellt
SENASTE
Redeye provides its initial take on Surgical Science’s Q1 2024 report, which featured contrasting developments for the company’s two business areas. We judge that notable positives from the report include the strategically important Industry/OEM segment exceeding our estimates and decent margins given the significant y/y sales decline. Notable negatives include anaemic Educational Products sales, which have led to overall figures coming in considerably below our estimates.
LÄS MER
